{
  "event_id": "cdf79f461f88",
  "ticker": "NVS",
  "company_name": "Novartis",
  "drug_name": "COSENTYX",
  "pdufa_date": "20231006",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:ERASURE, FIXTURE trials, NEJM",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.514239",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Moderate-to-severe plaque psoriasis",
    "source": "websearch:ERASURE, FIXTURE trials, NEJM",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.514241",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "secukinumab",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:34:43.330127",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Immunology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.971066",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:34:43.330127",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:ERASURE, FIXTURE trials, NEJM",
    "confidence": 0.95,
    "evidence": [
      "ERASURE, FIXTURE trials, NEJM"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.514226",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.001",
    "source": "websearch:ERASURE, FIXTURE trials, NEJM",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.514233",
    "error": null
  },
  "p_value_numeric": 0.001,
  "effect_size": {
    "status": "found",
    "value": "PASI 75: 81.6% (300mg) vs 4.5% placebo",
    "source": "websearch:ERASURE, FIXTURE trials, NEJM",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.514235",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",
    "A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen"
  ],
  "nct_ids": [
    "NCT01365455",
    "NCT01406938"
  ],
  "enrollment": {
    "count": 967,
    "type": "ACTUAL",
    "nct_id": "NCT01406938",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:28:58.534916"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:37:17.244720",
  "enriched_at": "2026-01-11T19:46:21.262714",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "1a90ec524360",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": false,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "IL-17A inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -827,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:41.203865",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:42:51.451885"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:42:51.451893"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:46:07.900530",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Cosentyx, Lumicef Get Orphan Status for Addâ€™l Indications"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:46:12.343904",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:46:13.609079",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:46:20.147262",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [
      "Novartis Wins FDA Approval for Intravenous Cosentyx ... Review - accessdata.fda.gov Cosentyx (secuki"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T19:46:21.262702",
    "search_status": "FOUND"
  }
}